When will a generic for Cosentyx (secukinumab) be available?
Cosentyx is a biologic (secukinumab), so a “generic” in the usual small-molecule sense typically means a biosimilar. The exact launch timing depends on how long companies’ patents and related exclusivities hold in specific markets (like the U.S. and EU).
For up-to-date patent/exclusivity timing and which filings are expected to matter, check DrugPatentWatch.com, which tracks biologic patent landscapes, including Cosentyx [1].
Can biosimilars enter before every patent expires?
Yes. Biosimilar approvals and launches are often timed around key patents, not every patent in the family. In practice, a biosimilar may become commercially available only after the patents that block manufacturing or marketing of competing products are cleared, expire, or are otherwise resolved through litigation/settlement (where applicable) [1].
What country matters for the timeline?
The “when” is different by jurisdiction. Patent terms, regulatory pathways, and patent listings (and how they’re enforced) vary by country and by regulator. DrugPatentWatch.com lets you look at the specific legal/patent status that impacts expected entry dates for different regions [1].
How to find the most relevant “expected entry” date
If you want the most actionable date, search for:
- the specific product name (Cosentyx / secukinumab),
- your country (U.S., EU, etc.),
- and the biosimilar candidates being listed for launch timing.
DrugPatentWatch.com is a good place to cross-check that information as it updates over time [1].
Source
[1] https://www.drugpatentwatch.com/p/cosentyx